enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Alnylam' Reveals Detailed 18-Month Data From Vutrisiran ... - AOL

   www.aol.com/news/alnylam-reveals-detailed-18...

   Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis.

3. Vutrisiran - Wikipedia

   en.wikipedia.org/wiki/Vutrisiran

   Plasma concentration profiles of vutrisiran showed rapid absorption and elimination from systemic circulation. There was a dose-proportional increase in peak plasma concentrations Cmax and a slightly greater than dose-proportional increase in AUC∞ inf and AUC last after a single subcutaneous dose across the dose range studied in the phase I trial in healthy volunteers.

4. Alnylam shares slide after heart drug data fails to impress ...

   www.aol.com/news/alnylam-shares-slide-heart-drug...

   The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran, in June. Vutrisiran was tested in patients with transthyretin ...

5. Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod - AOL

   www.aol.com/news/alnylams-alny-rare-disease-drug...

   The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

6. Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

   www.aol.com/news/alnylam-alny-files-maa-ema...

   Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

7. RNA interference - Wikipedia

   en.wikipedia.org/wiki/RNA_interference

   [129] [130] Vutrisiran is designed to break down the mRNA that codes for transthyretin. Other investigational drugs using RNAi that are being developed by pharmaceutical companies such as Arrowhead Pharmaceuticals, Dicerna, Alnylam Pharmaceuticals, Amgen, and Sylentis. These medications cover a variety of targets via RNAi and diseases.

8. Analysts Put Alnylam On Upside Catalyst Watch Ahead Of ... - AOL

   www.aol.com/news/analysts-put-alnylam-upside...

   RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) from $225 to $250. The analyst says that the company is confident that the recent APOLLO-B validates the ...

9. Alnylam Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Alnylam_Pharmaceuticals

   Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023. [40] In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension ...